Quality-Adjusted Survival in Allogeneic Hematopoietic Cell Transplant Patients
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 16-004618
Sponsor Protocol Number: 16-004618
About this study
The utilization of hematopoietic cell transplantation (HCT) has increased dramatically over the past decade. Although it is potentially lifesaving for a variety of primarily malignant diseases, allogeneic HCT carries a significant burden of short- and long-term morbidity with potential threats to quality of life (QOL), impairments in cognitive and psychological functioning, as well as impact on spiritual and philosophical view of life. The main aim of this pilot study is to evaluate treatment-related toxicity and clinical indicators of QOL in HCT patients, and to integrate these into a multidimensional quality-adjusted survival (QAS) model using the Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) method.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- English speaking
- 18 years of age or older
- Eligible to undergo allogeneic HCT and are predicted to be less than 30 days before transplant.
- Capable of completing questionnaires P
- Primary participants are asked to nominate one supportive person or caregiver (e.g., spouse, partner, family member, or friend) who accepts the patient’s nomination to be contacted by research personnel about the study, and who subsequently enrolls
Exclusion Criteria:
- Health status or verbal ability that would interfere with informed consent or completion of the interview without a proxy
- Those with a stated unwillingness or inability to complete the follow up assessments
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Mark Litzow, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available